Iotron, CIIC to produce radioisotope Cu-67

By staff writers

August 25, 2021 -- Iotron Medical and Canadian Isotope Innovations (CIIC) will produce the radioisotope copper-67 (Cu-67) for new cancer therapies.

This collaboration will increase the production capacity of facilities operated by CIIC in Saskatoon, Canada, making the radioisotope more widely available to international cancer researchers.

Though Cu-67 has long been known to be beneficial for personalized cancer therapy, it has been difficult to produce with sufficient quantity and purity using nuclear reactors or cyclotrons. A lack of a reliable supply of the radioisotope has prevented medical researchers from exploring its potential in new targeted cancer therapies, according to the company.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking